Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
- Revenue in USD (TTM)10.88bn
- Net income in USD236.00m
- Incorporated2016
- Employees58.00k
- LocationIQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703-8426United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.iqvia.com/
Mergers & acquisitions
| Acquired company | IQV:NYQ since announced | Transaction value |
|---|---|---|
| Corezetta Co Ltd | 10.77% | -- |
| Novasyte LLC | 13.68% | -- |
| Linguamatics Ltd | 24.24% | 72.14m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health Inc | 147.66bn | -4.15bn | 16.05bn | 49.50k | -- | 17.86 | -- | 0.1087 | -14.05 | -14.05 | 495.09 | 3.07 | 3.73 | 11.29 | 18.15 | 2,983,071.00 | -10.48 | 2.60 | -24.71 | 6.02 | 4.64 | 5.16 | -2.81 | 0.7268 | 0.4992 | 6.64 | 0.8985 | 59.41 | 6.38 | 9.83 | 300.44 | 3.22 | 5.67 | 9.50 |
| Incyte Corporation | 2.11bn | 404.96m | 16.85bn | 1.37k | 41.97 | 6.96 | 36.61 | 8.00 | 1.86 | 1.86 | 9.71 | 11.25 | 0.7351 | 13.01 | 8.06 | 1,541,896.00 | 14.12 | -1.91 | 16.70 | -2.33 | 95.88 | 96.44 | 19.21 | -2.44 | 5.01 | -- | 0.0205 | -- | 22.50 | 39.60 | 134.97 | -- | 76.69 | -- |
| AmerisourceBergen Corp. | 179.59bn | 818.37m | 18.77bn | 22.00k | 23.71 | 6.55 | 14.38 | 0.1045 | 3.84 | 4.02 | 843.54 | 13.92 | 4.67 | 15.20 | 14.45 | 8,163,142.00 | 2.13 | 2.11 | 8.53 | 8.73 | 2.78 | 2.78 | 0.455 | 0.4435 | 0.5771 | 12.96 | 0.6002 | 43.62 | 6.94 | 8.48 | -21.75 | 23.77 | 3.24 | 11.22 |
| Seattle Genetics, Inc. | 801.42m | -304.29m | 19.77bn | 1.30k | -- | 11.09 | -- | 24.67 | -1.87 | -1.87 | 4.93 | 10.40 | 0.4373 | 0.8087 | 4.68 | 615,531.50 | -16.60 | -16.85 | -18.87 | -20.59 | 91.56 | 88.47 | -37.97 | -31.44 | 4.49 | -4.91 | 0.00 | -- | 35.76 | 19.45 | -77.40 | -- | -0.8587 | -- |
| McKesson Corporation | 221.98bn | -674.00m | 27.95bn | 80.00k | -- | 4.31 | 58.35 | 0.1259 | -3.75 | -3.54 | 1,172.95 | 36.01 | 3.69 | 12.73 | 11.62 | 2,774,763.00 | -0.7607 | 3.15 | -2.22 | 8.61 | 5.33 | 5.75 | -0.2063 | 0.9135 | 0.5653 | 2.06 | 0.5036 | 15.38 | 2.86 | 9.30 | 93.42 | -- | 6.06 | 10.66 |
| Iqvia Holdings Inc | 10.88bn | 236.00m | 31.22bn | 58.00k | 137.28 | 5.09 | 21.44 | 2.87 | 1.17 | 1.21 | 54.05 | 31.60 | 0.4794 | -- | 4.52 | 187,603.50 | 1.21 | 2.15 | 1.44 | 2.66 | 34.37 | 32.04 | 2.52 | 3.61 | -- | 1.99 | 0.6435 | 0.00 | 7.32 | 15.35 | -27.97 | -0.2298 | 39.04 | -- |
| Regeneron Pharmaceuticals Inc | 7.62bn | 2.09bn | 38.49bn | 7.40k | 19.59 | 3.72 | 16.83 | 5.05 | 18.21 | 18.69 | 66.42 | 95.74 | 0.616 | 0.7459 | 3.13 | 1,029,959.00 | 16.88 | 17.74 | 19.37 | 20.75 | 92.21 | 92.91 | 27.40 | 23.68 | 3.51 | 25.23 | 0.0635 | 0.00 | 14.28 | 26.10 | 55.86 | 41.14 | 19.63 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2019 | 19.82m | 10.21% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 9.16m | 4.72% |
| SSgA Funds Management, Inc.as of 30 Sep 2019 | 7.34m | 3.78% |
| Fidelity Management & Research Co.as of 30 Sep 2019 | 5.44m | 2.80% |
| Jackson Square Partners LLCas of 30 Sep 2019 | 5.36m | 2.77% |
| Canada Pension Plan Investment Boardas of 30 Sep 2019 | 4.09m | 2.11% |
| Janus Capital Management LLCas of 30 Sep 2019 | 3.70m | 1.91% |
| Glenview Capital Management LLCas of 30 Sep 2019 | 3.62m | 1.86% |
| Lone Pine Capital LLCas of 30 Sep 2019 | 3.55m | 1.83% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2019 | 3.46m | 1.78% |
